Literature DB >> 32101703

Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation.

Sidhartha R Sinha1, Yeneneh Haileselassie2, Linh P Nguyen2, Carolina Tropini3, Min Wang4, Laren S Becker2, Davis Sim2, Karolin Jarr2, Estelle T Spear2, Gulshan Singh2, Hong Namkoong2, Kyle Bittinger5, Michael A Fischbach6, Justin L Sonnenburg7, Aida Habtezion8.   

Abstract

Secondary bile acids (SBAs) are derived from primary bile acids (PBAs) in a process reliant on biosynthetic capabilities possessed by few microbes. To evaluate the role of BAs in intestinal inflammation, we performed metabolomic, microbiome, metagenomic, and transcriptomic profiling of stool from ileal pouches (surgically created resevoirs) in colectomy-treated patients with ulcerative colitis (UC) versus controls (familial adenomatous polyposis [FAP]). We show that relative to FAP, UC pouches have reduced levels of lithocholic acid and deoxycholic acid (normally the most abundant gut SBAs), genes required to convert PBAs to SBAs, and Ruminococcaceae (one of few taxa known to include SBA-producing bacteria). In three murine colitis models, SBA supplementation reduces intestinal inflammation. This anti-inflammatory effect is in part dependent on the TGR5 bile acid receptor. These data suggest that dysbiosis induces SBA deficiency in inflammatory-prone UC patients, which promotes a pro-inflammatory state within the intestine that may be treated by SBA restoration.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bile acids; colitis; dysbiosis; inflammatory bowel disease; metabolomics; pouchitis; ulcerative colitis

Mesh:

Substances:

Year:  2020        PMID: 32101703      PMCID: PMC8172352          DOI: 10.1016/j.chom.2020.01.021

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  77 in total

1.  The bacterial pathogenesis and treatment of pouchitis.

Authors:  S D McLaughlin; S K Clark; P P Tekkis; R J Nicholls; P J Ciclitira
Journal:  Therap Adv Gastroenterol       Date:  2010-11       Impact factor: 4.409

2.  Microbiota-Derived Metabolic Factors Reduce Campylobacteriosis in Mice.

Authors:  Xiaolun Sun; Kathryn Winglee; Raad Z Gharaibeh; Josee Gauthier; Zhen He; Prabhanshu Tripathi; Dorina Avram; Steven Bruner; Anthony Fodor; Christian Jobin
Journal:  Gastroenterology       Date:  2018-02-01       Impact factor: 22.682

3.  Fasting-Mimicking Diet Modulates Microbiota and Promotes Intestinal Regeneration to Reduce Inflammatory Bowel Disease Pathology.

Authors:  Priya Rangan; Inyoung Choi; Min Wei; Gerardo Navarrete; Esra Guen; Sebastian Brandhorst; Nobel Enyati; Gab Pasia; Daral Maesincee; Vanessa Ocon; Maya Abdulridha; Valter D Longo
Journal:  Cell Rep       Date:  2019-03-05       Impact factor: 9.423

4.  Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases.

Authors:  Henri Duboc; Sylvie Rajca; Dominique Rainteau; David Benarous; Marie-Anne Maubert; Elodie Quervain; Ginette Thomas; Véronique Barbu; Lydie Humbert; Guillaume Despras; Chantal Bridonneau; Fabien Dumetz; Jean-Pierre Grill; Joëlle Masliah; Laurent Beaugerie; Jacques Cosnes; Olivier Chazouillères; Raoul Poupon; Claude Wolf; Jean-Maurice Mallet; Philippe Langella; Germain Trugnan; Harry Sokol; Philippe Seksik
Journal:  Gut       Date:  2012-09-19       Impact factor: 23.059

5.  Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis.

Authors:  Garrett C Zella; Elizabeth J Hait; Tiffany Glavan; Dirk Gevers; Doyle V Ward; Christopher L Kitts; Joshua R Korzenik
Journal:  Inflamm Bowel Dis       Date:  2010-09-15       Impact factor: 5.325

6.  Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis.

Authors:  Archana S Rao; Banny S Wong; Michael Camilleri; Suwebatu T Odunsi-Shiyanbade; Sanna McKinzie; Michael Ryks; Duane Burton; Paula Carlson; Jesse Lamsam; Ravinder Singh; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2010-08-04       Impact factor: 22.682

Review 7.  Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.

Authors:  Siddharth Singh; Andrea M Stroud; Stefan D Holubar; William J Sandborn; Darrell S Pardi
Journal:  Cochrane Database Syst Rev       Date:  2015-11-23

8.  Modulation of the fecal bile acid profile by gut microbiota in cirrhosis.

Authors:  Genta Kakiyama; William M Pandak; Patrick M Gillevet; Phillip B Hylemon; Douglas M Heuman; Kalyani Daita; Hajime Takei; Akina Muto; Hiroshi Nittono; Jason M Ridlon; Melanie B White; Nicole A Noble; Pamela Monteith; Michael Fuchs; Leroy R Thacker; Masoumeh Sikaroodi; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2013-01-16       Impact factor: 25.083

Review 9.  Pros and cons of antibiotic therapy for pouchitis.

Authors:  Udayakumar Navaneethan; Bo Shen
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2009-10       Impact factor: 3.869

10.  Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation.

Authors:  Benoit Chassaing; Gayathri Srinivasan; Maria A Delgado; Andrew N Young; Andrew T Gewirtz; Matam Vijay-Kumar
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

View more
  104 in total

1.  The microbiome: Composition and locations.

Authors:  Megan S Kennedy; Eugene B Chang
Journal:  Prog Mol Biol Transl Sci       Date:  2020-09-24       Impact factor: 3.622

Review 2.  Microbial modulation of intestinal T helper cell responses and implications for disease and therapy.

Authors:  Markus B Geuking; Regula Burkhard
Journal:  Mucosal Immunol       Date:  2020-08-13       Impact factor: 7.313

Review 3.  Cross Talk between Gut Microbiota and Intestinal Mucosal Immunity in the Development of Ulcerative Colitis.

Authors:  Junfeng Zou; Chen Liu; Shu Jiang; Dawei Qian; Jinao Duan
Journal:  Infect Immun       Date:  2021-08-16       Impact factor: 3.441

4.  Single-Cell Transcriptional Survey of Ileal-Anal Pouch Immune Cells From Ulcerative Colitis Patients.

Authors:  Joseph C Devlin; Jordan Axelrad; Ashley M Hine; Shannon Chang; Suparna Sarkar; Jian-Da Lin; Kelly V Ruggles; David Hudesman; Ken Cadwell; P'ng Loke
Journal:  Gastroenterology       Date:  2021-02-05       Impact factor: 22.682

Review 5.  Gut microbiome, liver immunology, and liver diseases.

Authors:  Rui Wang; Ruqi Tang; Bo Li; Xiong Ma; Bernd Schnabl; Herbert Tilg
Journal:  Cell Mol Immunol       Date:  2020-12-14       Impact factor: 11.530

Review 6.  Inflammatory Bowel Diseases (IBD) and the Microbiome-Searching the Crime Scene for Clues.

Authors:  Mirae Lee; Eugene B Chang
Journal:  Gastroenterology       Date:  2020-11-27       Impact factor: 22.682

Review 7.  The microbiome in inflammatory bowel diseases: from pathogenesis to therapy.

Authors:  Sheng Liu; Wenjing Zhao; Ping Lan; Xiangyu Mou
Journal:  Protein Cell       Date:  2020-06-29       Impact factor: 14.870

8.  Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection.

Authors:  Jessica R Allegretti; Colleen R Kelly; Ari Grinspan; Benjamin H Mullish; Jonathan Hurtado; Madeline Carrellas; Jenna Marcus; Julian R Marchesi; Julie A K McDonald; Ylaine Gerardin; Michael Silverstein; Alexandros Pechlivanis; Grace F Barker; Jesus Miguens Blanco; James L Alexander; Kate I Gallagher; Will Pettee; Emmalee Phelps; Sara Nemes; Sashidhar V Sagi; Matthew Bohm; Zain Kassam; Monika Fischer
Journal:  Inflamm Bowel Dis       Date:  2021-08-19       Impact factor: 5.325

Review 9.  Epigenome-metabolome-microbiome axis in health and IBD.

Authors:  Hajera Amatullah; Kate L Jeffrey
Journal:  Curr Opin Microbiol       Date:  2020-09-10       Impact factor: 7.934

10.  Barley Leaf Insoluble Dietary Fiber Alleviated Dextran Sulfate Sodium-Induced Mice Colitis by Modulating Gut Microbiota.

Authors:  Meiling Tian; Daotong Li; Chen Ma; Yu Feng; Xiaosong Hu; Fang Chen
Journal:  Nutrients       Date:  2021-03-05       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.